Skip to main content

Table 1 The clinical and biochemical properties of 600 participants

From: Circulating PCSK9 levels and 2-hPG are positively correlated in metabolic diseases in a Chinese Han population

 

All (n = 600)

NGT (n = 200)

IGR (n = 200)

T2DM (n = 200)

Age (years)

59.49 ± 8.06

59.01 ± 7.43

59.63 ± 8.05

59.84 ± 8.67

Male/female

248/352

79/121

86/114

83/117

SBP (mmHg)

136.63 ± 20.38

129.79 ± 19.31

137.05 ± 18.06b

143.12 ± 21.51b,d

DBP (mmHg)

80.77 ± 12.04

77.33 ± 10.53

81.34 ± 11.39 b

83.68 ± 13.24b

BMI (kg/m2)

24.75 ± 3.71

23.60 ± 3.41

25.46 ± 3.22b

25.19 ± 4.16b

WC (cm)

86.33 ± 9.32

83.67 ± 9.07

87.82 ± 9.30b

87.47 ± 9.05b

HC (cm)

97.13 ± 6.46

95.88 ± 6.32

97.90 ± 6.64 b

97.60 ± 6.24 a

WHR

0.89 ± 0.07

0.87 ± 0.07

0.89 ± 0.06 b

0.89 ± 0.06b

HR (per min)

78.73 ± 11.95

74.79 ± 10.59

80.16 ± 11.52 b

81.27 ± 12.69 b

HDL-C (mmol/L)

1.30 ± 0.32

1.34 ± 0.33

1.33 ± 0.32

1.23 ± 0.31b,d

LDL-C (mmol/L)

2.91 ± 0.71

2.78 ± 0.66

2.94 ± 0.64

2.99 ± 0.81a

TC (mmol/L)

5.00 ± 0.95

4.86 ± 0.88

5.09 ± 0.84a

5.05 ± 1.09

TG (mmol/L)

1.76 ± 1.29

1.38 ± 0.71

1.77 ± 0.95b

2.12 ± 1.82b,c

FBG (mmol/L)

6.30 ± 1.55

5.37 ± 0.36

6.13 ± 0.54b

7.40 ± 2.18b,d

2-hPG (mmol/L)

9.61 ± 4.26

6.21 ± 0.91

8.22 ± 1.51b

14.40 ± 3.86b,d

FINS (μIU/ml)

12.71 ± 13.72

10.13 ± 6.54

12.97 ± 11.70

15.03 ± 19.37b

2 h–INS (μIU/ml)

74.94 ± 62.64

47.41 ± 37.54

76.94 ± 59.63b

100.46 ± 73.66b,d

HOMA-IR

3.9 ± 0.1

2.43 ± 1.58

3.52 ± 3.15 a

4.97 ± 6.64 b,d

PCSK9 (ng/ml)

77.86 ± 35.43

65.33 ± 32.68

77.63 ± 28.14b

90.62 ± 39.96b,d

  1. SBP systolic blood pressure, DBP diastolic blood pressure, BMI body mass index, WC waist circumference, HC hip circumference, WHR waist-to-hip ratio, HR heart rate, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, TC total cholesterol, TG triglyceride, FBG fasting blood glucose, 2-hPG 2-h postchallenge plasma glucose, FINS fasting insulin, 2 h–INS 2-h postchallenge plasma insulin, HOMA-IR homeostasis model assessment-estimated insulin resistance index, PCSK9 Proprotein convertase subtilisin/kexin type 9
  2. Compared with NGT, ap < 0.05, bp < 0.01; Compared with IGR, cp < 0.05, dp < 0.01